An antisense oligonucleotide directed to a nucleic acid molecule encoding a human apolipoprotein B, wherein said oligonucleotide is 100% complementary to said nucleic acid molecule and is a chimeric single stranded oligonucleotide having 20 nucleotides in length and is composed of a central space region consisting of ten 2-deoxynucleotides flanked on both sides by flanks of five nucleotides 2-methoxyethyl compounds (2-MOE) nucleotides, and wherein the phosphorothioate internucleoside linkages are (P> = S) throughout the oligonucleotide, and wherein all cytidine residues are 5-methylcytidines, and wherein said oligonucleotide specifically hybridizes with and inhibits the expression of a nucleic acid encoding human apolipoprotein B, for use in: (a) treating an animal having a disease or condition associated with apolipoprotein B including lipid metabolism s abnormal (B) treating an animal having a disease or condition associated with apolipoprotein B including abnormal cholesterol metabolism (C) treating an animal having a condition associated with apolipoprotein B, wherein the condition is atherosclerosis (D) treating an animal having a condition associated with apolipoprotein B, wherein the condition is hyperlipidemia (E) treating an animal having a disease associated with apolipoprotein B disease, wherein the disease is diabetes (F) treating an animal having a condition associated with apolipoprotein B, wherein the condition is obesity (G) treating an animal having a disease associated with apolipoprotein B disease, wherein the disease is a cardiovascular disease (H) therapy or prophylaxis, wherein said use comprises modulating glucose levels in an animal (I) therapy or prophylaxis, wherein said use comprises modulating the levels of serum cholesterol in an animal (J) therapy or prophylaxis, wherein said use comprises modulating lipoprotein levels in an animal or (k) therapy or prophylaxis, wherein said use comprises modulating serum triglyceride levels in an anima
